Table 3.
Summary of worst dasatinib-related adverse event per participant
Adverse Event | CTCAE Grade | Stage 1 (n = 21) | Stage 1B (n = 29) |
---|---|---|---|
Worst nonhematological | 1 | 4 (19%) | 6 (21%) |
2 | 8 (38%) | 12 (41%) | |
3 | 8 (38%) | 5 (17%) | |
4 | 0 (0%) | 1 (3%) | |
5 | 0 (0%) | 0 (0%) | |
Worst overall | 1 | 0 (0%) | 5 (17%) |
2 | 8 (38%) | 11 (38%) | |
3 | 12 (57%) | 8 (28%) | |
4 | 0 (0%) | 1 (3%) | |
5 | 0 (0%) | 0 (0%) |
Includes adverse events in which relationship to protocol treatment is missing.